RCK2 is a newly characterized non-inactivating delayed rectifier K+ channel from rat brain with a distinct pharmacological profile.
Answers are grounded in this paper and cite their sources.
RCK2 profile in rat brain is hypothesis-generating; leaves open any role in human cardiac electrophysiology.
A novel member of the RCK family of rat brain K+ channels, called RCK2, has been sequenced and expressed in Xenopus oocytes. The K+ currents were voltage-dependent, activated within 20 ms (at 0 mV), did not inactivate in 5 s, and had a single channel conductance in frog Ringers of 8.2 pS. Compared to other members of the RCK family the pharmacological profile of RCK2 was unique in that the channel was resistant to block (IC50 = 3.3 microM) by charybdotoxin [(1988) Proc. Natl. Acad. Sci. USA 85, 3329-3333] but relatively sensitive to 4-aminopyridine (0.3 mM), tetraethylammonium (1.7 mM), alpha-dendrotoxin (25 nM), noxiustoxin (200 nM), and mast cell degranulating peptide (200 nM). Thus, RCK2 is a non-inactivating delayed rectifier K+ channel with interesting pharmacological properties.
No takes yet. Share an insight, caveat, or question.
Kirsch et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: